Bristol/Gilead submit Truvada/Sustiva combo
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb and Gilead's fixed-dosed combination of Bristol's Sustiva (efavirenz) and Gilead's Truvada (emtricitabine/tenofovir) could be on the market by the first quarter of 2007. Bristol completed the submission of the triple-combo antiretroviral in late April, putting an estimated standard review action date in February 2007. If approved, the combination "would be the first and only product that contains a complete highly active antiretroviral therapy [HIV] regimen in a single once-daily tablet," the firms note. While the sponsors initially ran into bioequivalence issues, they announced in January that they had obtained data supporting bioequivalence (1Pharmaceutical Approvals Monthly January 2006, p. 26)...
You may also be interested in...
Bristol-Myers Squibb and Gilead plan to submit an NDA in the second quarter for a fixed-dose combination of Bristol’s Sustiva (efavirenz) and Gilead’s Truvada (emtricitabine/tenofovir disoproxil).
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.